Vascular device developer Conor Medsystems reported that it has obtained a worldwide, nonexclusive license from Novartis Pharma for the use of the pharmaceutical pimecrolimus in its stents.
Pimecrolimus is a cell-selective inhibitor of the production and release of pro-inflammatory cytokines. Conor said it expects to begin a clinical trial this year evaluating the therapeutic potential of two stents incorporating pimecrolimus for the treatment of coronary artery disease.
Both stents will utilize the Menlo Park, CA-based company's reservoir-based cobalt chromium drug-eluting stent platform. One stent will be loaded with pimecrolimus, and the other will be a dual-drug stent loaded with both pimecrolimus and paclitaxel, the company said.
By AuntMinnie.com staff writers
March 16, 2006
Related Reading
Conor Medsystems initiates CoStar II trial, May 24, 2005
Conor Medsystems nets CE Mark, May 10, 2005
Conor Medsystems inks distribution deal, May 27, 2004
Conor Medsystems releases PISCES data, May 26, 2004
Conor Medsystems completes paclitaxel stent trial enrollment, March 25, 2004
Copyright © 2006 AuntMinnie.com
